ALEXIS AIDT-1

N/A

Report date: 2025/01/26 18:15:59

Base Information

Drug NameALEXIS AIDT-1
Drug Alias Nameanti-AIDT-1 CAR T-cell therapy (Kiromic Biopharma)anti-AIDT-1 CAR gamma delta T-cell therapy (Kiromic Biopharma)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaHematologic NeoplasmsLymphoma, Follicular +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKiromic Biopharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesKiromic Biopharma Inc
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaHematologic NeoplasmsLymphoma, Follicular +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A